Imugene | Cancer Immunotherapies
@TeamImugene
Followers
3,782
Following
842
Media
584
Statuses
1,412
A clinical stage immuno-oncology #biotech developing a range of new treatments seeking to activate the immune system of cancer patients. #Immunotherapy $IMU
Australia
Joined December 2015
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
#ENHYPEN_XO
• 321512 Tweets
President Putin
• 274576 Tweets
Vice President Trump
• 270853 Tweets
#OnlyIfYouSayYes
• 239882 Tweets
XO OUT NOW
• 132434 Tweets
#ROMANCE_UNTOLD_OutNow
• 132351 Tweets
#loveislandusa
• 131408 Tweets
VP Trump
• 128171 Tweets
Flamengo
• 112787 Tweets
Eminem
• 81078 Tweets
ESPYs
• 68843 Tweets
Serena
• 66449 Tweets
Highway 1009
• 59090 Tweets
バイデン
• 51246 Tweets
Natlan
• 42194 Tweets
Allan
• 38427 Tweets
renjun
• 38117 Tweets
Botafogo
• 37551 Tweets
NEW OST BY NUNEW
• 35301 Tweets
音楽の日
• 32809 Tweets
スタフィー
• 32047 Tweets
キィニチ
• 25721 Tweets
Kordell
• 24841 Tweets
杉山紀彰
• 23204 Tweets
#TheDeathOfSlimShady
• 22893 Tweets
マーヴィカ
• 21425 Tweets
Kaylor
• 18765 Tweets
オロルン
• 15575 Tweets
東山奈央
• 15085 Tweets
ムアラニ
• 14515 Tweets
シトラリ
• 14447 Tweets
シロネン
• 14258 Tweets
ファイルーズあい
• 13842 Tweets
イアンサ
• 12307 Tweets
チャスカ
• 12081 Tweets
Capitano
• 12026 Tweets
BROUGHT THE HEAT BACK
• 11030 Tweets
Our acquisition of the worldwide exclusive licence to a next-generation oncolytic virus (OV) technology, CF33, will include ex-Viralytics members as part of our project development team. Phase 1 clinical trial is anticipated to commence in 2020
#EndCancer
8
29
210
Join us on Thursday, November 11, 10am AEST for our 'Science Series'. This session will feature our oncolytic
#viraltherapy
CHECKvacc with Professor Yuman Fong and Dr. Yuan Yuan.
Register now: $IMU
@SoCalYuman
@YuanYuanMDPhD
#BreastCancer
$IMU.ax
#science
3
34
145
Imugene was on the
@SevenNetwork
last night showcasing the potential of our
#CF33
#oncolytic
virus to target and fight various
#cancers
and
#tumour
types.
A big thank you to the patients involved, Professor Yuman Fong for his scientific leadership, and
@amberlaidler7
for
8
36
144
CF33
Oncolytic Virus
We hope to improve the clinical benefits and quality of life for patients with cancers that are difficult to treat using current therapeutic approaches.
Developed by Professor Yuman Fong at the prestigious City of Hope.
Learn more
5
20
105
Learn more about our Oncolytic Virus CF33, invented by Professor Yuman Fong from City of Hope — and CHECKvacc, which is based on the CF33 platform with further enhanced tumour killing ability by adding an anti-PD-L1 antibody gene, which the virus delivers to the cancer cell. $IMU
0
24
105
“Having continued through the
#monotherapy
dose escalation unimpeded thus far, we’re eager to see
#VAXINIA
used in combination with the well-known Pembrolizumab drug and see the potential benefit this can bring to patients." - Leslie Chong, CEO $IMU
More:
6
21
90
“It is a great credit to our team that the Phase 1b study has been initiated and the first patient dosed, in under three months since acquiring the technology.”
- CEO, Leslie Chong $IMU
#CellTherapy
#AZERCELL
ASX news at
5
22
104
“The Fast Track process of drug development is designed to facilitate the development, and the review of drugs to treat serious conditions and fill an unmet medical need, with Fast Track status often leading to earlier drug approval and access by patients.”
- Leslie Chong $IMU
6
22
104
"This is the first treatment vaccine in any
#gastrointestinal
#cancer
and we have high hopes that it will be very successful... It feels like we're on the cusp of something really big here with this vaccine, we're very excited," Dr Tony Dhillon said.
🗞️First bowel cancer vaccine
8
20
99
"I am encouraged that we are seeing positive signals at such an early stage of our PD1-Vaxx Phase I trial and we are now progressing to the Phase 1b combination studies in treatment naïve patients..." - Leslie Chong, CEO $IMU
#FollowTheScience
Learn more:
1
19
96
We are proud to announce, effective prior to the open of trading on December 20th, that Imugene Limited will enter into the S&P/ASX 200 Index.
#FollowTheScience
$IMU
Read the S&P Dow Jones announcement:
11
16
96
Our next 'Science Series' will focus on our B cell immunotherapy, PD1-Vaxx, featuring our Senior Director of Clinical Science Dr Nimali Withana and Professor Pravin Kaumaya.
Wednesday, February 23
10:00am AEDT
Register now:
$IMU
#EndCancer
#Biotech
#ASX
6
27
94
“Interestingly, the same characteristics that eventually make cancer cells resistant to chemotherapy or radiation treatment actually enhance the success of oncolytic viruses, such as CF33-hNIS.”
- Yuman Fong
Learn more
$IMU
#immunotherapy
#oncolyticvirus
4
18
91
Today, our CEO & MD Leslie Chong met with the esteemed Dr. Yuman Fong at City of Hope to discuss the future of cancer treatment.
Dr. Fong, a leading cancer researcher, physician, and surgeon, has dedicated over 30 years to developing oncolytic viruses. Our lead candidate, CF33,
3
6
92
“We continue to rapidly advance our monotherapy dose while the combination study continues its positive progress. We remain incredibly eager to bring the results of this trial to our shareholders, patients and the wider public.” - Leslie Chong $IMU
ASX:
4
17
90
"CHECKvacc has the potential to improve clinical response and survival in this indication where there are currently no meaningful treatments, and we are eager to deliver on that.” - Leslie Chong, CEO $IMU
More:
#CHECKvacc
#OncolyticVirus
#Virotherapy
2
15
89
Biliary tract cancers are aggressive and often diagnosed late, limiting treatment options. At Imugene, we are developing innovative
#oncolyticviruses
like VAXINA and onCARlytics to potentially offer new hope for patients.
Learn more about the evolving treatment landscape for
1
17
90
We are pleased to announce new and significant HER-Vaxx data has been presented at the World Congress of Gastrointestinal Cancer in Barcelona. $IMU $IMU.ax
Visit:
9
23
88
“Still being less than 12 months since the very first patients were dosed, we’re now well advanced on amassing the critical data we require to publish on the outcomes of this study, and we remain very positive on the potential benefits ...” - Leslie Chong
3
11
86
“The start of our onCARlytics study which is first-in-class is a significant milestone for clinicians treating patients faced with the challenge of solid tumour cancers which to date have been untreatable with CD19-targeting biological drugs." Leslie Chong
2
19
85
We are pleased to receive and share this image today from Leslie Chong's presentation at the 2023 JP Morgan Healthcare Conference in San Francisco — the largest and most informative healthcare investment symposium in the
#biotechnology
industry. $IMU
#JPMorgan
#JPMHC23
#EndCancer
0
9
83
We are pleased to present positive final overall survival data from our Phase 2 study of HER-Vaxx in Her-2/Neu overexpressing advanced/metastatic gastric/GEJ cancer following analysis of safety and efficacy data.
Learn more:
$IMU
#GastricCancer
$IMU.ax
2
19
82
Imugene (
#ASX
: $IMU) well positioned to deliver 2024 milestones \ Media covered by
@SmallCapsASX
2
14
85
The first patient, with bile tract cancer, has been dosed in the intravenous monotherapy arm of the
#OASIS
trial of our
#virotherapy
drug candidate
#onCARlytics
(on-CAR-19, CF33-CD19 HOV4). The trial is a world-first in combining a CD19-expressing oncolytic virus with a
#CD19
1
19
83
“We are excited to commence this important
Phase 2 trial with PD1-Vaxx after being approached by the leading colorectal cancer oncologists from both Australia and the UK.”
- CEO, Leslie Chong $IMU
More at
#PD1Vaxx
#immunotherapy
4
18
81
We are pleased to provide a clinical trial update for our Phase 1 MAST trial evaluating the safety and efficacy of VAXINIA -- the trial has now cleared cohort 4 of the intravenous (IV) arm of the monotherapy dose escalation study, plus IV cohort 2 of the combination study. $IMU
6
16
82
We are pleased to announce onCARlytics technology in combination with Eureka Therapeutics' ARTEMIS® cell receptor platform has presented preclinical data at ASGCT demonstrating enhanced anti-tumour activity in vivo against hepatocellular carcinoma tumours.
0
18
78
Leslie Chong X Proactive interview following our ASX news today that we received positive early signals showing VAXINIA’s promise as a potent anti-cancer drug. Full interview at
$IMU Bringing Effective New Treatments And Options To Patients Who Need Them
6
17
80
We have announced a new clinical trial supply agreement with Merck KGaA, Darmstadt, Germany (ETR: MRK) and Pfizer Inc. (NYSE: PFE) to evaluate the safety and efficacy of HER-Vaxx.
ASX News:
Learn more about HER-Vaxx:
$IMU $IMU.ax
8
22
78
“Following the outstanding work of Professor Yuman Fong and the
@cityofhope
team, in addition to the positive pre-clinical results, we’re incredibly eager to unlock the potential of VAXINIA & the oncolytic
#virotherapy
platform more broadly.” Leslie Chong
4
14
77
We are pleased to announce
#onCARlytics
(CF33-CD19) oncolytic virus in combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells was presented at the Annual Meeting of the Society for Immunotherapy of Cancer (
#SITC
). $IMU
5
14
77
Azer-Cel has the potential to become the first ever approved Allo CAR T Cell Therapy for Cancer — designed to address high and growing unmet needs in the post auto CAR T setting of Diffuse Large B Cell Lymphoma (DLBCL), earlier lines of therapy and other blood cancer indications.
8
21
80
“With the US being the largest healthcare market in the world, this is a particularly important patent extension to protect our PD1-Vaxx technology as we continue its development.” - Leslie Chong, CEO $IMU $IMU.ax
Learn more:
4
16
78
“We are pleased with the results we have seen so far with no observed toxicity with early encouraging results in oncolytic virus infection and replication in the TNBC tumours ..." - Leslie Chong, MD & CEO $IMU $IMU.ax
#oncolyticvirus
4
20
77
Our mission is to develop transformative cancer medicines to improve patients’ lives and to establish value and trust with our stakeholders. We are supported by a leading team of cancer experts with extensive experience in developing new cancer therapies.
Meet Prof. Yuman Fong:
3
16
79
CEO Magazine is an iconic brand, which inspires excellence in business. 'The Immunity Card: Leslie Chong' discusses how our CEO found her niche & looks at our pipeline and the idea of using the body’s natural immunity to target and obliterate cancer.
$IMU
2
8
76
Sneak Peak:
Professor Yuman Fong, Keynote Speaker at this year's Bioshares Biotech Summit in Hobart, Tasmania.
@SoCalYuman
$IMU $IMU.ax
#Immunotherapy
3
12
78
"CF33 is completely unique, a new beast in the field of cancer landscape. There's nothing like it, it's an
#oncolytic
virus that expresses
#CD19
. Now that’s a protein that doesn't exist on solid tumour so what it does is it covers a solid tumour with a CD19 marker and as you
1
14
77
City of Hope has dosed the first cohort 2 patient in the Phase I
#clinicaltrial
of our oncolytic virotherapy candidate, CHECKvacc, an immune checkpoint inhibitor armed chimeric vaccinia poxvirus from the lab of
#CF33
inventor Professor Yuman Fong. ASX $IMU
4
14
76
"Dear Fellow Shareholders, we are writing to you regarding the share price performance of Imugene over the last few months and to point out that Imugene is as strong as it has ever been in its history."
- Paul Hopper and Leslie Chong
More:
$IMU
#EndCancer
4
6
77
New Analyst Coverage:
ROTH Capital Partners
"Highly Positive Final Phase 2 HER-Vaxx Survival Data Justifies More Trials"
• Price Target: 71c
Download the PDF:
$IMU
#immunotherapy
#medtech
$IMU.ax
1
10
75
Today, on
#WorldCancerDay
, we stand together against a disease that affects millions of people. Our mission is to develop transformative cancer medicines to improve patients' lives.
From our breakthrough CF33 virus to our CAR T-cell therapy azer-cel, we're developing weapons to
4
11
75
“Receiving this patent allowance for the CF33 family of oncolytic viruses from the US patent office is a crucial step forward & with the US being the largest healthcare market in the world, this is a particularly important patent milestone.” -Leslie Chong
1
14
75
ASX News:
Next cohort reached in intravenous arms of monotherapy and combination study for cancer-killing virus CF33-hNIS (VAXINIA)
More at
$IMU $IMU.ax
#CF33
#OncolyticVirus
#VAXINIA
1
12
76
Today we presented our PD1-Vaxx cancer checkpoint
#immunotherapy
program at the ESMO Congress 2021 Annual Meeting in Paris - clinical results continue to indicate PD1-Vaxx is showing early signs of immune responses in patients.
View: $IMU
#Antibodies
#ASX
2
14
72
We invite you to visit our investor section to read our latest analyst coverage from ROTH Capital Partners.
Their 12-month price target is AUD 0.71.
•
#CF33
#onCARlytics
#OncolyticVirus
$IMU $IMU.ax
1
10
63
Leslie Chong catches up with Proactive following our ASX news this morning: $IMU and
@cityofhope
dose first patient in cohort 3 of phase 1 trial to test cancer-killing oncolytic virus against
#breastcancer
.
Full Video:
#CHECKvacc
#ClinicalTrials
0
11
74
We're sending love and support to Kate Middleton as she bravely shares her
#cancer
diagnosis. Her courage in sharing her story shines a light on the crucial role early detection plays in fighting this disease.
It's important to shed light on the complexities of cancer diagnosis
2
10
70
"Imugene’s HER-Vaxx is a b-cell peptide cancer immunotherapy, which is injected like a vaccine, and designed to treat tumours that over-express a certain receptor known as HER-2/neu. This also occurs in types of breast, ovarian, lung & pancreatic cancers."
3
17
73
Professor Yuman Fong will give the keynote address at this year's Bioshares Biotech Summit, July 24-25 in Hobart, Tasmania.
Our Chief Business Officer, Monil Shah, will also be presenting.
Learn more:
$IMU
#oncology
#immunotherapy
#endcancer
$IMU.ax
0
15
73
“While it was pleasing to see the primary objective of safety and tolerability of
#CHECKvacc
confirmed, the imaging data presented showed several other positive outcomes resulting from our first-in-human trial ...”
-Leslie Chong $IMU $IMU.ax
Learn more:
3
18
73
New Analyst Coverage from BELL POTTER's John Hester: HER-vaxx Program To Expand
Valuation target: 52c
Download via:
$IMU Bringing Effective New Treatments And Options To Patients Who Need Them
#immunotherapy
#imugene
#investoralerts
5
17
73
"While many gene therapy companies focus on restoring lost functions to normal cells, the Australia-based immuno-oncology company Imugene is employing the method to help kill cancer cells. In 2019, the company acquired an oncolytic virus called CF33 ..."
3
11
71
Our Phase I IMPRINTER trial has been presented as a poster presentation at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) in Vienna, Austria.
Read our ASX News:
View the Poster Presentation:
$IMU
#LungCancer
#Biotech
1
8
71
We are pleased to announce an abstract detailing the Phase 1 CHECKVacc trial in adults with triple negative breast cancer has been published at the American Society of Clinical Oncology’s
@ASCO
2022 Annual Meeting.
More:
$IMU $IMU.ax
#ASCO
#BreastCancer
3
11
70
“As we continue to move through the cohorts at pace, we’re aiming to have this high-quality science peer reviewed & recognised within publications or conferences befitting of its results and potential benefit to patients in need.” - Leslie Chong $IMU
ASX
1
14
72
Our mission is to develop transformative cancer medicines to improve patients’ lives and to establish value and trust with our stakeholders.
|
#EndCancer
| $IMU
1
18
71
We created this short video called 'The Why' to show our passion and drive behind Team Imugene.
We work hard, every day, to achieve our mission of developing transformative cancer medicines to improve patients’ lives.
Visit our YouTube channel for more:
3
14
69
Introducing 'The Why' a short video illustrating the purpose and passion of 'Team Imugene' as we strive, daily, towards our mission to develop transformative cancer medicines to improve patients’ lives.
Watch now:
#endcancer
#immunotherapy
$IMU $IMU.ax
2
18
70
We are pleased to announce results from our Phase 1
#PD1Vaxx
IMPRINTER trial in adults with non-small cell
#lungcancer
has been published today in an abstract at the American Society of Clinical Oncology’s 2022 Annual Meeting.
More:
$IMU
#ASCO2022
@ASCO
2
9
69
"IMU is focused on advancing four platform technologies, Allo CAR T cell Therapy, CF33 Oncolytic Virus, onCARlytics and B Cell
#Immunotherapy
. The company is backed by an experienced management team with over 150 years of combined experience in drug development and approvals."
4
11
70
"To achieve two IND’s for our programs (OV and B Cell) concurrently is an outstanding result for the team.”
- Leslie Chong, CEO $IMU
#EndCancer
#HERVAXX
Read today's full
#ASX
announcement:
6
14
69
“Reliability of drug supply is a major hurdle for the clinical development of many modern biological oncology drug candidates. De-risking this critical component of clinical development by working with ABL is a significant milestone." - Leslie Chong $IMU
0
13
68
Our Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of our cancer-killing virus CF33-hNIS (VAXINIA) has progressed to the next stage.
Read our ASX announcement to learn more:
$IMU $IMU.ax
#EndCancer
#VAXINIA
#OncolyticVirus
2
17
69
"The completion of the monotherapy component of our Phase 1 trial will be a milestone for Imugene and clinicians treating Australians faced with the challenges of
#lungcancer
.” - Leslie Chong, CEO
PD1-Vaxx is a B-cell activating immunotherapy. $IMU
More:
1
11
68
Our Phase 1 clinical trial of CD19
#oncolytic
#virotherapy
drug candidate
#onCARlytics
has cleared its first cohort within the intratumoural monotherapy arm of the study and is ready to commence combination dosing solid tumour patients with CD19 targeting drug blinatumomab
1
7
70
“As this is our first Oncolytic Virotherapy in the clinic, it’s great to have no safety issues thus far with our first patient and we are very pleased to see our second patient joining ..." - Leslie Chong, CEO
Read our ASX news:
#OncolyticVirus
$IMU
4
19
68
Medical News Today provide in-depth coverage of
#VAXINIA
:
“We are keen to revolutionize cancer therapy, and no longer are we satisfied with incremental improvements in survival, we want to cure patients ..."
- Leslie Chong, CEO & MD
$IMU
#CancerTherapy
5
10
69
"Our onCARlytics platform opens up the possibility to treat solid tumours with existing CD19 targeting drugs and we are excited to see how Arovella's iNKT cell platform and other drugs in our trial perform on the back of our platform." - Leslie Chong $IMU
3
15
67
We've received a Notice of Grant from the Chinese Patent Office for our oncolytic virotherapy
#CF33
, including
#VAXINIA
and
#CHECKvacc
.
This patent, titled "CHIMERIC POXVIRUS COMPOSITION AND USES THEREOF," provides protection for the method of composition and method of use of
0
12
68
"Imugene has reached a new milestone, with the announcement the company will enter into the S&P/ASX 300Index, effective from the close of trade on September 17th. The index measures up to 300 of the ASX’s largest companies and is an important benchmark..." Leslie Chong CEO $IMU
2
4
67
Our CF33 Oncolytic Virus technology will be featured at the renowned Annual Meeting for the Society for Immunotherapy of Cancer (SITC), to be held in San Diego, USA on 1-5 November 2023. $IMU
Learn more:
1
12
67
Following the
@ASX
news of our clinical trial supply agreement with Merck KGaA and Pfizer, our CEO Leslie Chong catches up with Andrew Scott at Proactive Investors to provide more detail.
Watch now on our YouTube channel:
$IMU $IMU.ax
#ClinicalTrails
4
15
63
“Imugene receiving this IND approval for VAXINIA from the FDA is a crucial step forward. The start of our VAXINIA OV study is a significant milestone for clinicians treating patients faced with the challenge of solid tumour cancers." -Leslie Chong CEO $IMU
0
14
67
“With a pipeline of innovative
#immunotherapy
#vaccines
and oncolytic viruses including the revolutionary CD19-CF33 onCARlytics with at potential to help solid tumor patients together with CAR T therapy, I am enthusiastic to join this wonderful team..." - Dr Shah $IMU
#EndCancer
4
6
67
“Phase 1 trials are generally designed to look for safety, tolerability and early response signals to determine the optimal dose for further development. I am encouraged we are seeing positive signals ..."
- Leslie Chong, CEO $IMU $IMU.ax
#biotech
More:
2
13
67
FDA Fast Track designation is awarded to help important new therapies reach patients earlier. It is designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fill unmet medical needs.
Full interview
0
12
66
We have received a Notice of Allowance from the People's Republic of China Patent Office, which protects our HER-Vaxx
#immunotherapy
, currently in development for HER-2 positive
#gastriccancer
$IMU
#FollowTheScience
$IMU.ax
ASX News:
0
10
65
Congratulations
@PrecisionBioSci
, on the exciting new licensing deal with
@TGTherapeutics
for Azer-cel. This is a major step forward in the development of this promising cell therapy, further validating its potential in the treatment of
#autoimmune
diseases and other indications.
0
6
65
Our CEO and MD, Leslie Chong, discussed our four
#immunotherapy
platforms and the clinical advancements observed across our studies during the Capital HQ
#MasterClass
.
During the
#presentation
, Leslie elaborated on our innovative technologies driving
#cancer
treatment, including
3
12
67
Oncolytic viruses (OVs) are designed to both selectively kill tumour cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival. $IMU $IMU.ax
ASX:
Study ID: NCT05081492
1
15
64
“The boss of cancer-fighting outfit Imugene says now is the time for Australia to double down on investment in clinical trials infrastructure to become a magnet for global pharmaceuticals firms.”
$IMU
#endcancer
#cancer
2
11
65
"It’s an outstanding accomplishment to see Imugene collaborate with Roche, in combination with our PD1-Vaxx drug. PD1-Vaxx has shown a tolerable safety profile and encouraging efficacy in patients with non-small cell
#lungcancer
..." -Leslie Chong CEO $IMU
6
19
64
🗞️Imugene (
#ASX
: $IMU) plans Phase 1
#VAXINIA
MAST trial expansion to target bile duct
#cancer
| Media covered by
@proactive_au
.
0
9
64
Our Phase 1 CF33-hNIS (
#VAXINIA
) study, evaluating the novel
#cancer
-killing virus, continues to show positive early signals. The study has now dosed 38 heavily pre-treated patients, with CF33-hNIS administered alone or in combination with
#pembrolizumab
, either intravenously or
3
14
64
“It’s an outstanding accomplishment to see Imugene collaborate with Roche, in combination with our PD1-Vaxx drug. PD1-Vaxx has shown a tolerable safety profile and encouraging efficacy in patients with NSCLC ..." - Leslie Chong, CEO $IMU $IMU.ax
More:
0
19
66
HER-Vaxx gaining global traction at major oncology meetings:
|>
$IMU $IMU.ax
#medtech
#HERvaxx
#immunotherapy
Very smooth presentation by Dr Joshua Tobias from MedUniVienna at ESMO GI.
@TeamImugene
HER-Vaxx gaining global traction at major oncology meetings. The PD-8 HERIZON study
1
2
30
1
13
65
"The City of Hope-developed therapy, CF33-hNIS-antiPDL1, is genetically engineered from a naturally occurring virus (chimeric oncolytic orthopoxvirus). The patents covering CF33-hNIS-antiPDL1 have been licensed to Imugene Limited (ASX: $IMU) ..."
Learn more:
#Immunotherapy
#CF33
City of Hope has opened a first-in-human clinical trial evaluating the use of a cancer-killing oncolytic virus to treat patients with metastatic triple-negative
#breastcancer
.
3
11
60
1
11
62
Professor Yuman Fong & ABC Radio Hobart at the 17th Annual Bioshares Biotech Summit. $IMU $IMU.ax
Full Interview via:
0
16
65
If you missed this past Channel 7 News Exclusive on
#CF33
with Professor Yuman Fong and Leslie Chong (2019), we have reposted it again for your convenience as it provides great detail about the technology and its potential to cure cancer.
$IMU
#YumanFong
#Imugene
$IMU.ax
2
16
63
Professor Yuman Fong and Leslie Chong talk with Proactive about our
#CF33
news this morning where City of Hope has achieved a 'first-in-the-world' milestone for testing an
#oncolytic
virus in people with metastatic solid tumors.
YouTube:
#Immunotherapy
2
12
63
On Cholangiocarcinoma Day, we stand united in hope.
Cholangiocarcinoma is a rare, aggressive bile duct
#cancer
that develops in the bile ducts. While it is less common than other cancers, it is equally devastating to those who are affected.
Today, we remember those who have
2
9
63
DIAMOND EQUITY RESEARCH
IND Clearance Enables OnCARlytics to enter Human Clinical Trials
Valuation: A$0.46
$IMU $IMU.ax
0
13
62
“Following the outstanding work of Professor Yuman Fong, Dr Yuan Yuan and the
@CityofHope
team, in addition to the positive pre-clinical results, we’re incredibly eager to unlock the potential of
#CHECKvacc
..." - CEO Leslie Chong
$IMU
#BreastCancer
More:
4
15
61
Latest Diamond Equity Research: $IMU Price Target AUD $0.49
VAXINIA’s Releases Early Positive Data, PD1-Vaxx and Azer-cel Advancing Through Clinical Pipeline
View the full report here:
#equityresearch
#equityrelease
#CancerResearch
#CancerTherapy
3
17
63
The first patient was dosed at Adelaide's Queen Elizabeth Hospital under the direction of Principal Investigator, Professor Tim Price.
With the promising results we've seen from HER-Vaxx we are eager to take the next step in its development.
More:
$IMU
1
10
60
Leslie Chong X Proactive Investors
Interview Topic:
First patients dosed in monotherapy IT & IV cohort 3 of VAXINIA MAST trial
⤴
#CureCancer
1
14
62